Pharming Group N.V. (PHAR) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, everyone, and welcome to this Q1 2025 call. So I'm Fabrice Chiraki, I'm the CEO of Farming, and I will be joined on this call today by Stephen Torr, our chief commercial officer, Anurag Relin, our chief medical officer, and Jeroen Wackermann, our chief financial officer. Next slide. In this call, we'll be making forward-looking statements that are based upon our current insights and plans. As you very well know, this may differ from future results. Next slide. First of all, let me say that I had a great first three months at Farming. The passion and the commitment of all employees to serving rare disease patients is really palpable throughout the company, whether you are at the production facilities, at the headquarter, or with the field. And this mindset of going this extra mile is clearly part of the DNA of the company and not just a few words on a culture slide as I've seen it actually too often. Next slide. So everyone is clearly determined to realize the vision that we've set for the company, which is to make farming a leading global rare disease company with a diverse portfolio and presence in large markets. that leverages a proven and efficient clinical development supply chain and commercial infrastructure. Next slide. Our results in the first quarter of 2025 are a good illustration of the solid growth foundation that we have built to realize this vision. We've had a strong start of the year with our total revenues increasing by 42% in the first quarter and a significant improvement of our bottom line, which supported an upgrade of our full-year guidance. So going into a little more detail, RUCONEST grew 49% to $68.6 million, driven by a continued increase of new patient enrollment and the sustained expansion of our prescriber base, as well as a lower ...